Gozes Books

Professor Illana Gozes
Books, Book Chapters and Reviews

B.1 BOOK I Gozes (ed) Neuropeptide Techniques, 2007 Humana Press (Neuromethods Vol. 39)
B.2 BOOK CHAPTERS & REVIEWS
1. U.Z. Littauer, A. de Baetselier, I. Ginzburg and I. Gozes. Control of tubulin expression in the developing nervous system. In: Neurotransmitters and their receptors. (U.Z. Littauer et al. eds.) 547-557. John Wiley and Sons Ltd. 1980.
2. I. Gozes and U.Z. Littauer.   Microtubule protein:Tubulin. Scan. J. Immunol. Vol. 15 Suppl. 9, 299-316,1982. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=6763768&query_hl=1&itool=pubmed_DocSum)
3.   I. Gozes. Tubulin in the nervous system. Neurochem.Inter. 4, 101-120, 1982.
4. J. Podenphant, E. Bock, M. Thymana and I. Gozes. Isoelectric focusing and two-dimensional electrophoresis by the method of O'Farrell of 125 I-labelled antigens isolated by means of crossed immunoelectrophoresis. Scand. J. Immunol. Vol. 17, Suppl. 10, 283-287, 1983.
5. I. Gozes. Molecular aspects of vasoactive intestinal polypeptide biosynthesis. In: Molecular Biology Approach to the Neuroscience. H. Soreq (ed.), IBRO Handbook Series, Methods in the Neurosci., 7,133-140. Wiley and Sons 1984.
6. I. Gozes. Vasoactive intestinal polypeptide - from gene to peptide. In: Gene Expression in brain, C. Zomzely-NeurathaBooks, Book Chapters and Reviewsnd W.A. Walker (eds.) pp. 275-296. John Wiley and Sons Ltd. 1985.
7. I. Gozes, M. Bodner, Y. Shani and M. Fridkin. Detection of mRNAs containing regulatory peptide sequences using synthetic oligodeoxynucleotide probes. UCLA Symposia on Molecular and Cellular Biology, New Series, Vol. 24, Neurobiology, Molecular Biology Approaches to Understanding Neuronal Function and Development, P. O'Lague (ed.), pp. 2130. Alan R. Liss, Inc., New York. 1985. (Appeared also in a Journal, ref. 23).
8. I. Gozes.   VIP gene expression.   Brain Peptides Update-volume 1.   J.B. Martin, M.J. Brownstein and D. Krieger (eds.), Chapter 10, pp. 141-162. John Wiley and Sons Ltd. 1987.
9. I. Gozes. Biosynthesis and regulation of expression. The vasoactive intestinal peptide gene. Ann N Y Acad Sci. 1988;527:77-87. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=3291702&query_hl=1&itool=pubmed_DocSum)
10. I. Gozes.   Basic principles of gene expression. ETP/ENA/IBRO, Practical Course on Molecular Neuroanatomy F.W. Van Leeuwen, R.M. Buijs and C.W. Pool (eds.),   Netherlands Institute for Brain Research, University of Amsterdam, pp.35-55 (1987).   Also in Techniques and Behavioral and Neural Sciences, Series, Editor: J.P. Huston, pp. 3-24. Elsevier Press, 1989.
11. A. Blumenfeld, I. Gozes, F.B. Axelrod, H. Maayan, O. Peleg, S. Godfrey, J.A. Trofatter, L. Ozelius, P. Schacter, R. Avidor, J.L. Haines, J.F. Gusella and X.O. Breakfield. Linkage analysis in familial dysautonomia. In: Genetic Diversity Among Jews. Diseases and Markers at the RNA
Level. B. Bonne-Tamir and A. Adam Eds. Oxford University Press. Chapter 16, pp. 179-193, 1992.
12.   I. Gozes, A. Davidson, M. Draui and T.W. Moody. The VIP gene is expressed in non-small cell lung cancer cell lines. Biomedical Res. 13 (Suppl. 2) 37-39, 1992.
13.   T.W. Moody, F. Zia, A.L. Goldstein, P.H. Naylor, E. Sarin, D.E. Brenneman, A.M.C. Koros, J.C. Reubi, L.Y. Korman, M.Fridkin and I. Gozes. VIP analogues inhibit small cell lung cancer growth. Biomedical Res. 13 (Suppl. 2) 131-135,1992.
14.   W. Rostene, M. Dussaillant, P. Denis, I. Gozes, M.-N. Montagne and A. Berod. Distribution and regulation of vasoactive intestinal peptide mRNA and binding sites in the mammalian eye, brain and pituitary. Biomedical Res. 13 (Suppl. 2) 63-69, 1992.
15. I. Gozes and D.E. Brenneman. Vasoactive intestinal peptide: from molecular genetics to neurotropism. Proceedings of the 12th international Washington spring symposium on growth factors, peptides and receptors. T. W.Moody Ed. Plenum Press, pp. 15-20, 1993.
16. Editor (together with Dr. E. Brenneman) of a special collection of manuscripts concerning neuropeptides as growth factors for the Journal of Molecular Neuroscience, (see ref.60), 1993.
17. I. Gozes and M. Fridkin. Lipophilic vasoactive intestinal peptide: potential drug for noninvasive impotence treatment. Proceedings of the 2nd JAPAN symposium on peptide chemistry. Peptide Chemistry 1992. Editor, N. Yanaihara. Publisher: ESCOM. pp. 442-445, 1993.
18. I. Gozes, J. Glowa, D.E. Brenneman, S.K. McCune, E. Lee and H. Westphal. Learning deficiencies in transgenic mice with reduced brain vasoactive intestinal peptide. Polish Journal of Chemistry, Proceedings of the 1st Polish-Israeli Symposium Chemistery and Biology of Peptides Volume 68, pp.1057-1060, 1994.
19. I. Gozes, M. Fridkin, H. Westphal, J. Glowa, A. Reshef, S.Zhukovsky, T. Waner, A. Niska, S. Rubinrout, G. Lilling, A.Davidson, R. Glazer-Steiner, T.W. Moody, W. Rostene and D.E.Brenneman. Neuronal VIP: from gene to sexual behavior, memory and clinical applications. The Proceedings of the International Symposium on VIP, PACAP and related regulatory peptides, 314-324, 1994.
20. J.M. Hill, R.F. Mervis, J. Politi, S.K. McCune, I. Gozes, M. Fridkin and D.E. Brenneman. Blockade of VIP during neonatal development induces neuronal damage and increases VIP and VIP receptors in brain. Ann. N.Y. Acad. Sci. Vol. 739, 211-225, 1994. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=7832475&query_hl=1&itool=pubmed_DocSum)
21. I. Gozes, D.E. Brenneman, G. Lilling, A. Davidson and T.W.Moody. Neuropeptide regulation of mitosis. Ann. N.Y. Acad.Sci. 739, 253-261, 1994.   (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=7832478&query_hl=1&itool=pubmed_DocSum)
22. I. Gozes, M. Fridkin and D.E. Brenneman. Stearyl-Nle-VIP: anon-invasive impotence drug and a potent agent of neuro-protection. Drugs of the Future, 20,680-685, 1995.
23. I. Gozes, G. Lilling, A. Davidson, A. Bardea, A. Reshef, R.Glazer, R. Zamostiano, O. AshurFabian, A. Ticher, I.E.Ashkenazi, S. Rubinraut, M. Fridkin and D.E. Brenneman. Development of VIP agonists and antagonists with tissue and receptor specificity: effects on behavioral maturation, sexual function and the biologic clock. Ann N.Y. Acad.Sci., Vol. 805, 159-171, 1996. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=8993401&query_hl=1&itool=pubmed_DocSum
24. D.E. Brenneman, J.M. Hill, I.Gozes and T.W. Phillips. Cytokines and neuropeptides. Ann N.Y. Acad. Sci. Vol. 805, 280-289, 1996. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=8993410&query_hl=1&itool=pubmed_DocSum)
25. I. Gozes, Y. Nesher, G. Lilling, M. Fridkin, S. Rubinraut, D.E. Brenneman, T.W. Moody and C. Chaimof. Inhibition of colon cancer by VIP antagonism through a cancer-associated VIP receptor. Proceedings of the 15th World Congress of Collegium Internationale Chirugiae, 819821, 1996.
26. I. Gozes, A. Bardea, M. Bechar, O. Pearl, A. Reshef, R.Zamostiano, A. Davidson, S. Rubinraut, E. Giladi, M. Fridkin and D.E. Brenneman. Neuropeptides and neuronal survival: neuroprotective strategy for Alzheimer's disease. Ann. N.Y. Acad. Sci. 814, 161-166, 1997. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=9160968&query_hl=1&itool=pubmed_DocSum)
27. D.E. Brenneman, T.M. Philips, B.W. Festoff and I. Gozes. Identity of neurotrophic molecules released from astroglia by vasoactive intestinal peptide. Ann. N.Y. Acad. Sci. 814, 167-173, 1997. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=9160969&query_hl=1&itool=pubmed_DocSum)
28. A. J. Harmar, A. Arimura, I. Gozes, L. Journot, M. Laburthe, J. R. Pisegna, S. R. Rawlings, P. Robberecht, S. I. Said, S. P. Sreedharan, S. A. Wank and J. A. Waschek. International Union of Pharmacology XVIII. Nomenclature of receptors for Vasoactive Intestinal peptide (VIP) and Pituitary Adenylate Cyclase Activating Polypeptide (PACAP). Pharmacological Reviews, 50, 265-270, 1998. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=9647867&query_hl=23&itool=pubmed_DocSum)
29. A. J. Harmar, A. Arimura, I. Gozes, L. Journot, M. Laburthe, J.R. Pisegna, R. Rawlings, P. Robberecht, S.I. Said, S.P. Sreedharan, S.A. Wank and J.A. Waschek. VIP and PACAP receptors The IUPHAR Receptors Compendium. Pp. 257-265, 1998
30. I. Gozes. The enigma of neuroprotection. Journal of Chemical Neuroanatomy,15, 130-131, 1998.
31. I. Gozes. The 4th International Congress of Neuroendocrinology and the 25th Annual Meeting of the Japan Neurochemistry Society. Investigational Drugs, weekly highlights, week 43, ending Wednesday, 28th October, Current Drugs Ltd pp. 49-51, 1998.
32. I. Gozes. In memory of Victor Mutt. Discoveries of biologically important peptides. J. Mol.
Neurosci.11, 105-108, 1998 (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=10096036&query_hl=23&itool=pubmed_DocSum)
33. I. Brown and I. Gozes. Stress genes in the nervous system during development and aging diseases. Ann. NY Acad. Sci. USA, 851, 123-128, 1998 (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=9668614&query_hl=1&itool=pubmed_DocSum)
34. I. Gozes, M. Bachar, A. Bardea, A. Davidson, O. Pearl, S. Rubinraut, M. Fridkin, E. Giladi and D.E. Brenneman. Preventive treatment of Alzheimer's disease: peptide-mediated neuroprotection. Progress in Alzheimer’s and Parkinson’s diseases. Plenun Publishing Corp., New York, NY, USA. pp.635-642, 1998.
35. I. Gozes, O. Perl, R. Zamostiano, S. Rubinraut, M. Fridkin, L. Shochat, and L.M. Lewin. Multiple action of a hybrid PACAP antagonist: neuronal cell killing and inhibition of sperm motility. Ann. NY Acad. Sci. USA, 865, 266-273, 1998. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=9928021&query_hl=1&itool=pubmed_DocSum)
36. D.E. Brenneman, G. Glazner, J.M. Hill, J. Hauser, A. Davidson and I. Gozes VIP neurotropism in the central nervous system: multiple effectors and identification of a femtomolaracting neuroprotective peptide. Ann. NY Acad. Sci. USA, 865, 207-212, 1998. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=9928014&query_hl=1&itool=pubmed_DocSum)
37. T. W. Moody, J. Leyton, I. Gozes, L. Lang and W.C. Eckelman. VIP and breast cancer. Ann. NY Acad. Sci. USA, 865, 290-296, 1998. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=9928023&query_hl=1&itool=pubmed_DocSum)
38. D.E. Brenneman, J.M. Hill, P. Gressens and I. Gozes. Neurotrophic action of VIP: from CNS ontogony to therapeutic strategy. In: Proinflammatory and Anti inflammatory Peptide. S.I. Said (Editor). In: Lung Biology in Health and Disease, Marcel Dekker, Inc. Chapter 17, pp. 383-408, 1998.
39.   Brenneman, D.E., Hill, J.M. and Gozes, I.   Vasoactive intestinal peptide in the central nervous system. In Psychopharmacology: 4th Generation of Progress, Stanley Watson, ed., Lippincott-Raven, Philadelphia.    CD-ROM Format.
40. R. Granoth, M. Fridkin and I. Gozes. Neuropeptides and skin cell function: VIP and stearyl[Nle17]VIP effects on HaCaT cells. Frontiers in Peptide Science, Proceedings of the 15th American Peptide Symposium [Nashville, June 14-19, 1997 (1999)] pp. 749-750. Ed. James P. Tam Pravin T.P. Kaumaya, ESCOM/Kluwer publications.
41. I. Gozes. American Society for Neuroscience 30th Annual Meeting. Investigational Drugs, weekly highlights, week 13, ending Wednesday, 31 March, Current Drugs Ltd pp. 20-22, 1999.
42. I. Gozes, R. Zamostiano, M. Fridkin and D.E. Brenneman. Peptide derivatives as potent neuroprotectants: relevancy to Alzheimer’s disease. Alzheimer’s Disease ans Related Disorders
Edited by: K. Iqbal, D.F. Swaab, B. Winbald and H.M.Wisniewski. John Wiley & Sons, Chapter 80, pp. 707-713, 1999.
43. I. Gozes, M. Bassan, R. Zamostiano, A. Pinhasov, A. Davidson, E. Giladi, O. Perl, G.W. Glazner and D.E. Brenneman. A novel signaling molecule for neuropeptide action:activitydependent neuroprotective protein. Ann N Y Acad Sci 897, 125-135, 1999. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=10676441&query_hl=1&itool=pubmed_DocSum)
44. J.M. Hill, G.W. Glazner, S.J. Lee, I. Gozes, P. Gressens and D.E. Brenneman. Vasoactive intestinal peptide regulates embryonic growth through the action of activity-dependent neurotrophic factor. Ann N Y Acad Sci. 897, 92-100, 1999. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=10676438&query_hl=1&itool=pubmed_DocSum)
45. D.E. Brenneman, J. Hauser, T.M. Phillips, A. Davidson, M. Bassan and I. Gozes Vasoactive intestinal peptide. Link between electrical activity and glia-mediated neurotrophism. Ann N Y Acad Sci 897, 17-26, 1999. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=10676432&query_hl=1&itool=pubmed_DocSum)
46. D.E. Brenneman, C.Y. Spong and I. Gozes. Protective peptides derived from novel glial proteins. Biochem Soc Trans. 28, 452-455, 2000. Erratum in: Biochem Soc Trans 2000 Dec;28(6):983 (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=10961938&query_hl=1&itool=pubmed_DocSum)
47. I. Gozes, R. Zamostiano, A. Pinhasov, M. Bassan, R. A. Steingart and D.E. Brenneman. A novel VIP responsive gene: activity-dependent neuroprotective protein. Ann N Y Acad Sci. 921,115-118, 2000. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=11193814&query_hl=1&itool=pubmed_DocSum)
48. I. Gozes. Alzheimer’s disease: My point of view. J. Molec. Neurosci 17(2): 269-270, 2001. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=11816798&query_hl=23&itool=pubmed_DocSum)
49. I. Gozes. Neuroprotective peptide drug delivery and development: potential new therapeutics. Trends in Neuroscience, 24(12),700-705, 2001. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract& list_uids=11718874&query_hl=23&itool=pubmed_DocSum)
50. I. Gozes, D. E. Brenneman, P. Geppetti, A. J. Kastin, R. E. Mains, T. W. Moody, A. D. Spier and M. Zimmermann. Neuropeptides: brain messengers of many faces. Trend in Neuroscience, 24(12),687-690, 2001. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=11718856&query_hl=23&itool=pubmed_DocSum)
51. I. Gozes and D.E. Brenneman. Activity-Dependent Neurotrophic Factor. Encyclopedia of Molecular Medicine. John Wiley Press. Volume 5, pp. 41-44. 2002.
52. I. Gozes. Neuropeptides in the new millennium: remembering friends who are no longer with us: Shmariahu Blumberg and Noboru Yanaihara. J. Molec. Neurosci. 18, 1-3, 2002.
53. I. Gozes, S. Furman, R. A. Steingart, A. Pinhasov, I. Vulih, J. Romano, R. Zaltzman, R. Zamostiano, E. Giladi, S. Rubinraut, M. Fridkin, J. Hauser and D. E. Brenneman. Femtomolaracting neuroprotective peptides: application for inhibition of Alzheimers disease. in: drug discovery and development for Alzheimer's disease 2000.   Springer Publishing Company, Proceedings of the first ISOA investigators meeting (H. Fillit and A. OConnonel editors) 204214, 2002.
54. I. Gozes Tau as a drug target in Alzheimer's disease. J Mol Neurosci. 2002 Dec;19(3):337-8. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=12540061&query_hl=1&itool=pubmed_DocSum)
55. T.W. Moody and I. Gozes. Summer Neuropeptide Conference - 12th Annual Meeting 29 June - 3 July 2002, Marco Island, FL, USA, Neuropeptides, Neuropeptides. 36(5):371-86, 2002.
56. I. Gozes, E. Giladi, A. Pinhasov, S. Furman, J. Romano, R. A. Steingart, S. Rubinraut, and M. Fridkin. Intranasal delivery of bioactive peptides or peptide analogues enhances spatial memory and protects against cholinergic deficits. In: The Proceedings of the 44th Oholo Conference: The Blood Brain Barrier Drug Delivery and Brain Pathology. 363-370.
57. I. Gozes Summer Neuropeptide Conference - 12th Annual Meeting 29 June - 3 July 2002, Marco Island, FL, USA; Investigational Drugs weekly highlights; Week 29, ending Friday 19th July 2002, pp. 30-32
58. I. Gozes and A. D. Spier. Peptides as drug candidates in Alzheimer’s disease. Drug Development Research. 56, 475–81, 2002.
59. M. Zimmermann, S.D. Brain, P. Geppetti, I. Gozes, D. Hoyer, M. Lakomy, W. Meyerhof, M. Michalkiewicz, I. Neumann, J.Z. Nowak, B. Przewlocka, J. Quinn, P.W. Reeh, J. Szolcsanyi. Report on the Meeting of the European Neuropeptide Club in Olsztyn, Poland, 22. – 25.05.2002, Neuropeptides, 36,435-493, 2002.
60. I. Gozes Neuroscience collaborations meeting report: the Israel Society for Neuroscience, and the Institute of Neurosciences, Mental Health and Addiction in Canada, first joint meeting, Sunday, Dec. 15, 2002, Eilat, Israel. J Mol Neurosci. 2003;21(1):55-6. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=14500995&query_hl=1&itool=pubmed_DocSum)
61. I. Gozes, Executive Editor: Preface vol. 9(6) Peptide - Based Drug Design; I. Gozes and S. Furman. VIP and Drug Design. Current Pharmaceutical Design, 9(6), 48394.2003. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=12570811&query_hl=11&itool=pubmed_DocSum)
62 Gozes I, Furman S. Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update. Best Pract Res Clin Endocrinol Metab. 2004 Dec;18(4):623-40.
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=15533779&query_hl=1&itool=pubmed_docsum)
63. Gozes I. Apolipoprotein E knockout mice as a model of behavioral dysfunction. J Mol Neurosci. 2004;23(3):149-50. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=15181242&query_hl=1&itool=pubmed_docsum)
64. Aracil A, Belmonte C, Calo G, Gallar J, Gozes I, Hoyer D, Patachini R, Schmidt RF, Zimmermann M. Proceedings of Neuropeptides 2004, the XIV European Neuropeptides Club meeting. Neuropeptides. 2004 Dec;38(6):369-71. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=15651126&query_hl=1&itool=pubmed_docsum
65. Gozes I. Parkinson's and Alzheimer's diseases: protein aggregations and neuroprotection. J Mol Neurosci. 2004;24(3):333-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list _uids=15655257&query_hl=1&itool=pubmed_docsum
66. Gozes I. Neuroprotection Encyclopedia of Neuroscience, Third Addition EsevierEditors George Adelman and Barry H. Smith (CD ROM).
67. D. Dangoor, S. Rubinraut, M. Fridkin and I. Gozes. Novel extended and branched N and C terminal analogs of vasoactive intestinal peptide. Pp. 814-815. Peptides 2004, The Proceedings of the 28th European peptide Sympsoium (kenes International Organization.
68. I. Gozes. Peptide fragments of large proteins providing potent neuroprotection: activitydepedent neuroprotective protein and NAP. Pp. 136- 139. Peptides 2004, The Proceedings of the 28th European peptide Sympsoium (kenes International Organization.
69. I. Gozes, I. Vulih, I. Spivak-Pohis and S. Furman. Neuroendocrine aspects of the molecular chaperones ADNF and ADNP. In: Molecular Chaperones and Cell Signalling, Edited by Brian Hendeson and Graham Pockley. pp. 251-262, Cambridge University Press, 2005.
70. I. Gozes VIP- and PACAP-Related neuroprotection. In: Handbook of Biologically Active Peptide. Edited by Abba J. Kastin pp. 1379-1384 2006 Elsevier Inc.
71. I. Gozes, J. Tiong From concept to potential therapeutics: Neuroprotective peptides. In: Handbook of Neurochemistry and Molecular Neurobiology Editor-in-chief: Lajtha, Abel 3rd ed., 2007,
72. I. Gozes I. Tau pathology and future therapeutics, Curr Alzheimer Res. 2010 Dec;7(8):68596. http://www.ncbi.nlm.nih.gov/pubmed/20678069
73. I. Gozes Davunetide (NAP) pharmacology: Neuroprotection and tau. In Emerging Drugs and Targets for Alzheimer's Disease. A. Martinez, editor. Cambridge: Royal Society of Chemistry. 108-128. 2010.
74. I. Gozes. VIP-PACAP 2010: my own perspective on modulation of cognitive and emotional behavior.J Mol Neurosci. 2010 Nov;42(3):261-3.
http://www.ncbi.nlm.nih.gov/pubmed/20922501
75. I. Gozes. Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate. Peptides. 2011 Feb;32(2):428-31. Epub 2010 Nov 2. Review http://www.ncbi.nlm.nih.gov/pubmed/21050875
76. I. Gozes. NAP (davunetide) provides functional and structural neuroprotection. Curr Pharm Des. 2011;17(10):1040-4. Review. http://www.ncbi.nlm.nih.gov/pubmed/21524250
77. I. Gozes. Microtubules (tau) as an Emerging Therapeutic Target: NAP (Davunetide). Curr Pharm Des. 2011; 17(31):3413-7. http://www.ncbi.nlm.nih.gov/pubmed/21902667
78. A.J. Harmar, J. Fahrenkrug, I. Gozes, M. Laburthe, V. May, J.R. Pisegna, D. Vaudry, H. Vaudry, J. A. Waschek, and S. I. Said, 2012. IUPHAR Reviews 1: Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Br J Pharmacol. 2012 Jan 31. doi: 10.1111/j.1476-5381.2012.01871.x. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/22289055
79. M. Gold, S. Lorenzl, A.J. Stewart, B.H. Morimoto, D.R. Williams and I. Gozes. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatric Disease and Treatment (Dovepress). February 2012 Volume 2012:8 Pages 85 - 93 DOI: http://dx.doi.org/10.2147/NDT.S12518
80. I. Gozes. Neuropeptide GPCRs in neuroendocrinology: The case of Activity-Dependent Neuroprotective Protein (ADNP). Front. Endocrin., | doi: 10.3389/fendo.2012.00134 http://www.frontiersin.org/Neuroendocrine_Science/10.3389/fendo.2012.00134/full
81. I. Gozes and P.Baas. Activity-Dependent Neuroprotective Protein (ADNP) and Davunetide (NAP). In: Handbook of Biologically Active Peptide. Edited by Abba J. Kastin, Second Edition, Section XVIII, section editor : Illana Gozes (section pp. 1611-1653). Academic Press, pp. 16111618.
82. S. Oz and I. Gozes. 2013. The cytoskeleton as a pharmacological target. In: The Cytoskeleton, imaging, isolation and interaction R. Dermietzel, Editor). Neuromethods 79: 151-169.
83. A. Del Carmen Alonso, E. Elakkad, C. Gong, F Liu, T. Tanaka, T. Kudo, Y. Tatebayashi, J. Pei, J. Wang, S. Khatoon, M. Flory, B. Ghetti, I. Gozes, M. Novak, M. Novak, N.K. Robakis, M. de Leon, M. Iqbal. 2013. Inge Grundke-Iqbal, Ph.D. (1937-2012): the Discoverer of the Abnormal Hyperphosphorylation of Tau in Alzheimer's Disease. J Mol Neurosci. 2013 Jan 30. [Epub ahead of print]